Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amplifon Enters U.S. Hearing Care Market As Bausch & Lomb Bows Out

This article was originally published in The Gray Sheet

Executive Summary

Privately held Italian hearing care firm Amplifon S.p.A. is gaining access to the American market through the acquisition of the Miracle-Ear hearing aid business from Bausch & Lomb. Announced July 12, the deal is expected to close by the end of the summer.

You may also be interested in...



Bausch & Lomb

Sale of B&L's Miracle-Ear hearing aid business to privately held Italian firm Amplifon, S.p.A. is complete, the company announces Aug. 30 (1"The Gray Sheet" July 19, p. 5). Sale of B&L's final non-core business, Charles River Laboratories, to Global Health Care Partners, a unit of investment banking firm Donaldson, Lufkin & Jenrette's private equity fund, DLJ Merchant Banking, is expected to close by the end of September

Bausch & Lomb

Sale of B&L's Miracle-Ear hearing aid business to privately held Italian firm Amplifon, S.p.A. is complete, the company announces Aug. 30 (1"The Gray Sheet" July 19, p. 5). Sale of B&L's final non-core business, Charles River Laboratories, to Global Health Care Partners, a unit of investment banking firm Donaldson, Lufkin & Jenrette's private equity fund, DLJ Merchant Banking, is expected to close by the end of September

B&L Hydroview IOL Approvable Vote Includes Modification To Incision Size

Bausch & Lomb's Hydroview Model H60M intraocular lens (IOL) is approvable for refilling the functionally intact human capsule following cataract removal provided labeling include a recommended mean incision size of 3.9 mm (+/- 2 standard deviations), FDA's Ophthalmic Devices Panel unanimously agreed (12-0) at its July 23 meeting.

Related Content

UsernamePublicRestriction

Register

MT012045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel